Loomis Sayles & CO L P Akero Therapeutics, Inc. Transaction History
Loomis Sayles & CO L P
- $77.3 Billion
- Q2 2025
A detailed history of Loomis Sayles & CO L P transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Loomis Sayles & CO L P holds 540,788 shares of AKRO stock, worth $29.2 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
540,788
Previous 488,938
10.6%
Holding current value
$29.2 Million
Previous $19.8 Million
45.8%
% of portfolio
0.04%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
299Shares Held
92.3MCall Options Held
1.72MPut Options Held
901K-
Janus Henderson Group PLC London, X06.74MShares$364 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$309 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$301 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$296 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$244 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.5B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...